Bull and Bear

Bull and Bear

Verdict: Watchlist — the recovery thesis is plausible but unconfirmed, and the margin question is genuinely unresolved. Both sides have legitimate evidence. The bull's strongest card is the post-crisis balance sheet and operational recovery; the bear's strongest card is that mid-cycle margins may be structurally lower than the market assumes. Q4 FY2026 results (expected May 2026) will decide which side is right — this is the single most important data point for this stock. Until that evidence arrives, conviction is premature in either direction.

Bull Case

Bull targets ₹380 (35x normalized FY2027 PAT of ₹135 Cr assuming 9% OPM recovery on ₹1,650 Cr revenue) within 12-18 months. Primary catalyst: Q4 FY2026 results showing OPM above 8%. Disconfirming signal: OPM below 5% despite Gondal at scale.

Bear Case

Bear targets ₹180 (25x mid-cycle PAT of ₹50 Cr assuming 5% structural OPM) within 6-12 months. Primary trigger: Q4 FY2026 OPM below 6% despite Gondal at scale. Cover signal: Two consecutive quarters with OPM above 9%.

The Real Debate

Verdict

Verdict: Watchlist. The bear carries slightly more weight today because the burden of proof falls on the recovery thesis, and Q3 FY2026 margins (5.0% OPM) have not yet reached the 8%+ level that would validate the bull. The critical tension is normalized OPM — every other question (valuation, quality, strategy) flows from whether this business structurally earns 8-9% or 5-6%. The bull could absolutely be right if Gondal capacity ramp delivers operating leverage through FY2027, and the extreme promoter alignment (81.5% ownership) provides genuine protection against governance-related value destruction. The verdict changes from Watchlist to Lean Long on two conditions: (1) Q4 FY2026 OPM prints above 8%, and (2) receivables decline below ₹600M without revenue decline. Until both are met, this is a "watch and wait" at current prices.